• Gary D. Blackford

    • Chairman of the Board

    Gary D. Blackford was elected to our Board in October 2014.  He was appointed Chairman of our Board in April 2020, and Chair of the Compensation Committee in April 2021. From 2002 until February 2015, Mr. Blackford was the Chairman of the Board and Chief Executive Officer of Universal Hospital Services, Inc. (NYSE: UHS), a leading nationwide provider of medical technology outsourcing and services to the health care industry. Mr. Blackford was the Chief Executive Officer of Curative Health Services, Inc., a specialty pharmacy and health services company, from 2001 to 2002. He was also the Chief Executive Officer of ShopforSchool, Inc., an online retailer, from 1999 to 2001.  Mr. Blackford has also been a director of ReShape Lifesciences, Inc. (NASDAQ: RSLS) since 2016 (and Lead Director since 2019), Children’s Hospitals and Clinics of Minnesota since 2017 (and Chairman since 2020), and Lifespace Communities, Inc., a not-for-profit organization, since February 2022.  He was a director of Wright Medical Group, N.V. (NASDAQ: WMGI) from 2008 to 2020 and PipelineRX, Inc. from 2016 to 2020.  Mr. Blackford was selected to serve as a member of our Board of Directors due to his executive leadership experience as a chief executive officer, financial literacy and experience in finance and accounting, international experience, and governance and public company board experience.


    Dr. Lisa Egbuonu-Davis was elected to our Board in March 2023. She is a member of our Compliance Committee and Governance Committee. Since 2021, Dr. Egbuonu-Davis has served on the Board of Directors of Omega Healthcare Investors, Inc. (NYSE: OHI), a real estate investment trust focused on healthcare-related real estate properties. She is a member of that company’s Nominating and Corporate Governance Committee. Since July 2023, she has served on the Board of Directors of Phreesia, Inc. (NYSE: PHR), a provider of software solutions that improve the operational and financial performance of healthcare organizations. From 2019 to July 2023, Dr. Egbuonu-Davis served as Vice President, Medical Innovations for DH Diagnostics, LLC, an affiliate of Danaher Corporation (NYSE:DHR), where she provided medical advice to influence research, partnership and investment strategy across Danaher’s diagnostic platform businesses. During that period, she served at various times as Interim Chief Medical Officer of Leica Biosystems and Beckman Coulter Diagnostics, both affiliates of Danaher Corporation. From 2015 to 2019, she served as Vice President, Global Patient Centered Outcomes and Solutions at Sanofi, Inc. (NASDAQ:SNY). At Sanofi, Dr. Egbuonu-Davis created patient programs, services and tools to enhance adherence and health outcomes in patients with chronic conditions. Prior to Sanofi, Dr. Egbuonu-Davis co-founded and served as director for ROI Squared, LLC, a privately-held life science company focused on diagnostic medical devices, and served as managing director for LED Enterprise, LLC, where she advised biopharmaceutical companies and trade associations on health care reform, technology assessment, quality metrics and incentives and implications for research and services. She also served in senior advisor roles for Avalere Health and Booz Allen Hamilton. She also previously served for 13 years in various roles at Pfizer, Inc. (NYSE:PFE), where she led clinical and outcomes research departments, supported product value assessments in support of reimbursement and adoption and influenced product investment and development decisions. She has served on the Johns Hopkins Medicine Board of Trustees since 2021 and the National Advisory Council for the Johns Hopkins University School of Education since 2007.

  • Indrani L. Franchini

    Indrani L. Franchini, J.D., was elected to our Board in July 2024. She is a member of our Audit Committee and our Compliance Committee. From January 2022 to March 2024, Ms. Franchini served as Executive Vice President, Chief Legal Officer and Secretary of Alnylam Pharmaceuticals, Inc.. From June 2017 to July 2021, she served as Executive Vice President and Chief Compliance Officer at Alexion Pharmaceuticals, Inc., where she led a comprehensive transformation of the company’s compliance program. Prior to that, Ms. Franchini held various roles in legal and compliance at Hess Corporation, a Fortune Global 500 leader in oil and gas exploration and production, most recently as Chief Compliance Officer and Assistant Corporate Secretary. Ms. Franchini also spent nearly 10 years at Pfizer in various positions, including supporting the Global Pharmaceutical business. Upon graduating from law school, Ms. Franchini practiced law at Milbank LLP, where she spent six years working in the firm’s New York and Tokyo offices.

  • Patrick J. O’Leary

    Patrick J. O’Leary was elected to our Board in October 2014. He is the Chairman of our Audit Committee.  Mr. O’Leary served as Executive Vice President and Chief Financial Officer of SPX Corporation (NYSE: SPXC), a global industrial and technological services and products company, from December 2004 until August 2012, when he retired. Prior to that time, he served as Chief Financial Officer and Treasurer of SPX Corporation from October 1996 to December 2004.  Mr. O’Leary has been a director and Chairman of SPX Corporation since 2015.  He was a Director of PulteGroup, Inc. (NYSE: PHM), from 2005 to 2018. Mr. O’Leary has been selected to serve as a member of our Board of Directors due to his executive leadership experience as a chief financial officer, financial literacy and experience in finance and accounting, international experience, and governance and public company board experience.

  • Dr. Julie Shimer

    Dr. Julie Shimer was elected to our Board in October 2014. She is the Chairwoman of the Governance Committee and a member of the Audit Committee and Compensation Committee. Dr. Shimer is currently a private investor and has 30 years of product development experience, including many years with major communications companies. From March 2007 to April 2012 she served as Chief Executive Officer of Welch Allyn, Inc., a manufacturer of frontline medical products and solutions, having served on the board of directors beginning in July 2002. Previously, Dr. Shimer was President, Chief Executive Officer, and a member of the board of directors of Vocera Communications, Inc., a provider of wireless communications systems. She also has served as general manager at 3Com Corporation and Motorola and has been a product development leader at Motorola and AT&T Bell Laboratories. Dr. Shimer also serves as a director of Apollo Endosurgery, Inc. (NASDAQ: APEN), a medical device company focused on less invasive therapies for the treatment of obesity. She was previously a director of Masimo Corporation, a medical technology company, Windstream Holdings, Inc., a leading telecommunications and cloud services provider, Earthlink, Inc., an internet service provider, and Netgear, a computer networking company.  She has served as the Chair of Empire State Development Corp., the State of New York's economic development organization, and as an advisor to two private companies, Kitchology, a mobile platform empowering families dealing with special diets through the power of technology and community, and CPLANE Networks, a leader in end-to-end data center and wide area network service orchestration that enables software-defined networking and network function virtualization services to be launched and managed in a single environment. She also serves as a director of Wycliffe USA.  Dr. Shimer was selected to serve as a member of our Board of Directors due to her leadership experience as a chief executive officer, knowledge of, and experience in, the healthcare industry, international experience and governance and public company board experience.

  • Joseph F. Woody

    Joseph F. Woody is our chief executive officer and a member of our board of directors. He brings 20 years of healthcare leadership experience, proven success driving revenue growth and expertise in spearheading portfolio transformations to our business.  

    Prior to joining Halyard, Joe served as chief executive officer and president of Acelity, where, since 2011, he was responsible for overseeing the development and commercialization of their $2 billion innovative wound care and regenerative solutions business. From 2009 to 2011, Joe served as global president, vascular therapies, for Covidien, creating their new vascular division and leading the company’s $2.6 billion acquisition and integration of ev3.

    Prior to his time at Covidien, Joe served as Smith & Nephew’s global president, advanced wound management, and Alliance Imaging’s vice president, Pacific operations. Joe previously served as board director for Acelity, the Advanced Medical Technology Association (AdvaMed) and Systagenix Wound Management. He also served as Chair of AdvaMed’s Wound Healing and Tissue Regeneration Sector.